Forbius announces the first patient dosed in a Phase 1 oncology trial of AVID200, a novel TGF-beta 1 andamp; 3 inhibitor

Source: CBNB

2019/02/12

Source: Company press release, 8 Jan 2019 , 8 Jan 2019 , Website: http://www.biospace.com Forbius, a clinical-stage company developing biologics for the
treatment of cancer and fibrosis, announced on 8 Jan 2019 that the first
patient was dosed in a Phase 1 clinical trial with AVID200. The trial will
evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects
of escalating doses of AVID200 in patients with solid tumours. AVID200
selectively neutralizes TGF-beta 1 and 3 with best-in-class pM potency, thus
neutralizing the principal immunosuppressive TGF-beta isoforms. AVID200's
optimal selectivity was also designed to circumvent cardiac and other safety
issues that have limited the applicability of older-generation,
non-selective TGF-beta inhibitors. AVID200's immuno-oncology mode of action
focuses on the reversal of both immunosuppression and fibrosis in the tumour
stroma. In syngeneic mouse tumour models, AVID200 treatment led to T-cell
activation, increased immune cell infiltration, and increased efficacy of
immune checkpoint agents. Original Source: Forbius, 2019. From website:
http://www.biospace.com. Released to ICIS 12 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey, godfreyj@elsevier.com, +44 (0) 1223 463167]